New treatment for high phosphate levels in kidney disease patients
Immobilized phosphate receptors for the treatment of hyperphosphatemia
This study is testing a new way to help people with chronic kidney disease and those on dialysis lower their high phosphate levels in the blood by using special materials that can quickly and safely remove excess phosphate, offering a better option than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11251527 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, particularly affecting patients with chronic kidney disease and those on dialysis. The approach involves creating specialized columns that can quickly and safely remove excess phosphate from the bloodstream using advanced materials that selectively bind phosphate. By utilizing lanthanide complexes attached to dendritic polypeptides, the research aims to provide a more effective solution than current dietary restrictions and oral phosphate binders, which often fall short in managing this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic kidney disease or those undergoing maintenance hemodialysis who struggle with high phosphate levels.
Not a fit: Patients with normal phosphate levels or those not affected by kidney disease are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the management of hyperphosphatemia, reducing complications and improving quality of life for patients with kidney disease.
How similar studies have performed: Preliminary results from similar approaches using lanthanide complexes have shown promise, indicating potential for success in this novel treatment strategy.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Pierre, Valerie C. — University of Utah
- Study coordinator: Pierre, Valerie C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.